Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

NCT05212662 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor is not pursuing the COVID-19 indication at this time.

Conditions

COVID-19
COVID-19 Acute Respiratory Distress Syndrome

Interventions

DRUG: TTI-0102
DRUG: Placebo

Sponsor

Thiogenesis Therapeutics, Inc.